US equities |
NVDA $239.24 ▲+0.14% MU $1,045.56 ▼-1.73% SPCX $171.92 ▲+0.49% AMD $649.42 ▲+2.80% MRVL $287.01 ▲+5.81% AVGO $375.81 ▲+3.67% INTC $112.50 ▼-3.18% MSFT $529.30 ▲+0.78%
FinancialContent

Intellia Therapeutics, Inc. - Common Stock (NQ:NTLA)

12.37 -0.38 (-2.98%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Intellia Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >
News headline image
Could This Cathie Wood Stock Soar in 2027? ↗
This biotech has grabbed plenty of headlines recently. 
Via The Motley Fool
News headline image
Intellia Eyes Lonvo-z Launch as HAE PDUFA Nears, TTR Study Advances ↗
Intellia Therapeutics (NASDAQ:NTLA) executives outlined plans for a potential launch of its hereditary angioedema treatment, lonvo-z, while discussing the company’s ongoing Phase III program in... 
Via MarketBeat
Topics Intellectual Property
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
Ark Invest was a buyer of tech stocks down as much as 53% from their recent all-time highs. 
Via The Motley Fool
Topics ETFs
Intellia Therapeutics (NASDAQ:NTLA) Slips on Q2 Revenue Miss Despite In-Line Loss ↗
Via Chartmill
Intellia Therapeutics Inc (NASDAQ:NTLA) Reports Strong Q4 2025 Revenue Beat and Confirms Key 2026 Pipeline Milestones ↗
Via Chartmill
News headline image
Intellia (NTLA) Q2 2026 Earnings Call Transcript ↗
Lonvo-z Phase III trial met primary endpoint with 87% attack reduction versus placebo. 
Via The Motley Fool
Topics Earnings
News headline image
Intellia Therapeutics Q2 Earnings Call Highlights ↗
Intellia Therapeutics (NASDAQ:NTLA) said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the... 
Via MarketBeat
Topics Earnings Intellectual Property
News headline image
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics ↗
This new technology could one day significantly expand the market for gene-editing biotechs. 
Via The Motley Fool
News headline image
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% ↗
It might pull it off, provided several things fall right in place. 
Via The Motley Fool
News headline image
Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why. ↗
This biotech player is heading for a critical moment. 
Via The Motley Fool
News headline image
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026? ↗
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare. 
Via The Motley Fool
News headline image
This Stock Is Up 58% This Year. Is It too Late to Buy? ↗
There could be additional catalysts for this drugmaker over the next year. 
Via The Motley Fool
News headline image
1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't ↗
This particular sector may suit cautious and aggressive investors. 
Via The Motley Fool
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
One of these stocks plummeted 49% on Tuesday. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
3 Biotech Stocks That Could Benefit from the Patent Cliff ↗
Via MarketBeat
Topics Intellectual Property
Top movers in Friday's after hours session ↗
Via Chartmill
News headline image
2 Healthcare Stocks to Buy and 1 to Approach With Caution ↗
Recent performances don't tell the whole story. 
Via The Motley Fool
News headline image
This Cathie Wood Stock Is Up 47% This Year: Is It Too Late to Buy? ↗
This run could be short-lived. 
Via The Motley Fool
Topics Death
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The growth investor kicked off this week by buying up some hard-hit stocks. 
Via The Motley Fool
News headline image
Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:GERN),(NASDAQ:NTLA),(NASDAQ:NAGE),(NASDAQ:OCGN) EQNX::TICKER_END 
Via FinancialNewsMedia
News headline image
Why Did NTLA Stock Jump 10% In Pre-Market Today? ↗
The company announced that the U.S. FDA lifted a clinical hold on its Phase 3 trial of ATTR-CM treatment drug. 
Via Stocktwits
News headline image
Intellia (NTLA) Q4 2025 Earnings Call Transcript ↗
Intellia (NTLA) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy? ↗
Will this biotech's innovative platform finally pay off? 
Via The Motley Fool
News headline image
NTLA Stock Jumped 13% Today – What Is The Latest FDA Action All About? ↗
The U.S. Food and Drug Administration lifted the clinical hold on a Phase 3 Trial, which was imposed on October 29, 2025 following the observation of Grade 4 liver transaminases and increased total... 
Via Stocktwits
Nasdaq, S&P 500 Futures Edge Higher Ahead Of Long Weekend: Why NVDA, MU, NTLA, ASTS Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Cathie Wood’s ARK Made Just One Buy Last Session — And It’s A Biotech Stock Up Nearly 30% YTD ↗
ARK doubles down on a CRISPR bet as Intellia Therapeutics’ stock heads for its best week since October. 
Via Stocktwits
Topics Artificial Intelligence ETFs
News headline image
Intellia CEO Sells $314K in Stock While Holding Over 1 Million Shares ↗
Focused on CRISPR-based therapies for rare diseases and oncology, this biotech just reported a notable insider sale in public filings. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech’s Resurgence: How a Year-End Rally and M&A Frenzy Set the Stage for 2026
As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
2 Beaten-Down Stocks That Will Soar in 2026, According to Wall Street ↗
Don't get too excited about their prospects. 
Via The Motley Fool
Topics Death
News headline image
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗
Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
21 22 Next >